With a planned merger in the works, Frequency Therapeutics is no longer advancing its remyelination therapies for multiple sclerosis (MS), and instead is exploring “strategic alternatives for the program,” the company has announced. The regenerative medicine company, which had aimed to develop a new approach to treating MS…
research
Relapsing-remitting multiple sclerosis (RRMS) patients with elevated levels of chloride in their cerebrospinal fluid (CSF), the fluid that bathes the central nervous system, may be at a higher risk of relapse, according to a study from China. Researchers propose that CSF chloride levels equal to or higher than 123.2…
Since their launch in the 2010s, the use of oral disease-modifying treatments (DMTs) for multiple sclerosis (MS) has increased substantially, while injectable DMTs have become less popular, according to a study based on U.S. commercial health insurance data. “While two injectable therapies known as platform injectables, were once the…
People with multiple sclerosis (MS) are at a greater risk than the general public of developing any type of dementia, with that of Alzheimer’s disease being more than twice as high and vascular dementia nearly four times as high, a study from Korea suggested. This risk also was higher…
People with multiple sclerosis (MS) living in the U.K. who identified as South Asian reported their first symptoms at a significantly younger age than self-reported white and Black individuals, according to preliminary data from the ADAMS project. ADAMS, which stands for the genetic Association study of individuals from…
A new formulation of Ocrevus (ocrelizumab), given as a 10-minute under-the-skin injection, was comparable to the approved intravenous version of the therapy in people with multiple sclerosis (MS), according to top-line results from a Phase 3 clinical trial. The medication’s developer, Roche, is planning to submit data from…
Inflammation in the membranes around the brain may trigger an inflammatory response that can spread into nearby brain tissue, a new study in a mouse model of multiple sclerosis (MS) shows. Researchers say these findings may help to advance scientists’ understanding of the mechanisms that underlie brain damage in…
INmune Bio‘s experimental therapy XPro1595 may promote myelin restoration through the activation of two types of nervous system support cells, according to new data that may lead to novel treatment strategies for multiple sclerosis (MS) and other neurodegenerative disorders. The findings highlight the activation of microglia, key…
Elevated blood levels of neurofilament light chain (NfL), a marker of nerve damage, are associated with long-term disability progression in people with multiple sclerosis (MS) — even among those without acute relapses or MRI disease activity — a study revealed. The results demonstrate the potential utility of NfL blood…
Tysabri (natalizumab) is better than five other disease-modifying therapies (DMTs) at reducing relapses and preventing disability worsening in relapsing-remitting multiple sclerosis (RRMS), according to the findings of a novel simulated clinical trial that directly compared the six treatments. The analysis used mathematical modeling to emulate a clinical trial…
Adding optic nerve damage — reflected by a thinning of the nerve layer in the eye’s retina — to the existing diagnostic criteria for multiple sclerosis (MS) was found to enhance diagnostic accuracy among people who had a single, MS-like event, according to a new study. The study “demonstrated…
A European Union (EU) initiative is bringing scientists together to develop an artificial intelligence (AI)-based platform that could help in predicting the course of multiple sclerosis (MS) for each person. The consortium’s project, which aims to “offer clinicians a holistic overview of the MS patient” — from disease…
Mavenclad (cladribine) is equally as effective as Gilenya (fingolimod) in reducing relapse rates among multiple sclerosis (MS) patients with highly active disease, according to a new real-world comparison. Disability worsening and the development of new lesions also were similar between the two patient groups — but…
Women with multiple sclerosis (MS) are three times more likely to face problems with sexual intimacy than are their healthy counterparts, according to a recent meta-analysis. About 61% of women with MS were estimated to have some degree of sexual dysfunction, with the most common being low…
Outcomes are better for people with relapsing-remitting multiple sclerosis (RRMS) initially treated with higher efficacy disease-modifying therapies (DMTs) than for those who begin with lower efficacy DMTs and escalate to more effective treatments as the disease progresses, according to a real-world analysis of patient registry data. Findings also…
Up to five years of treatment with Kesimpta (ofatumumab) continues to keep the number of relapses and brain lesions low in people with relapsing forms of multiple sclerosis (MS), with most patients showing no evidence of disease activity. These are new data from the ongoing ALITHIOS study…
Nerve cells coated with myelin — the fatty substance that’s lost in multiple sclerosis (MS) — may be more vulnerable to degeneration in an inflammatory environment than cells lacking myelin, researchers working in MS patient tissues and mouse models report. The scientists believe the phenomenon arises when certain…
Researchers have developed computer algorithms that may be able to predict certain aspects of cognitive change in multiple sclerosis (MS) patients. The prediction models, constructed using data from an electronic, self-administered test of information processing speed given MS patients, might accurately identify those likely to experience cognitive worsening over…
The director of the Multiple Sclerosis Center of Catalonia (CEMCAT) has been recognized with the 2023 Charcot Award, a prestigious prize that honors researchers for their lifetime work toward understanding multiple sclerosis (MS). Xavier Montalban, MD, PhD, has contributed to several areas of MS research and clinical care…
Gadoquatrane, a gadolinium-based contrast agent (GBCA) that may be safer than current agents for people undergoing MRI scans, has entered a Phase 3 clinical testing program. Quanti CNS (NCT05915702), one of the three global trials in Bayer‘s development program, will assess gadoquatrane against an…
Cigarette smoking significantly slows recovery time from a relapse for people with relapsing-remitting multiple sclerosis (RRMS), according to a pilot study in Iran. Similar links with relapse recovery were not seen for tobacco use with water pipes or exposure through second-hand smoke, also known as passive smoking. Findings add…
Aubagio (teriflunomide), an approved therapy for relapsing forms of multiple sclerosis (MS), works by shifting the balance between activated subsets of nerve-damaging immune cells to those with immunosuppressive traits, a new study reveals. Further studies to understand how changes in immune cell subsets drive Aubagio’s clinical effectiveness will…
Researchers identified a genetic variant that associated with faster multiple sclerosis (MS) progression and greater brain tissue damage, according to a study that combined data on more than 12,500 patients in North America, Europe and Australia. Unlike previously detected MS-related variants linked to the immune system, this variant sits…
Diet was found to significantly influence the severity of multiple sclerosis (MS) symptoms among patients living in Denmark in a new real-world study. A diet rich in plant-based products was generally associated with a lower symptom burden than one high in red and processed meats. The same was true…
Switching from Tysabri (natalizumab) to Ocrevus (ocrelizumab) does not appear to increase disease activity in people with relapsing forms of multiple sclerosis (MS) and stable disease, with most patients continuing to show no relapses or brain imaging findings one year after the transition, a clinical study shows.
Starting treatment with a high-efficacy disease-modifying therapy (DMT), rather than one with lesser efficacy, may reduce the number of times people with multiple sclerosis (MS) switch therapies due to a lack of effectiveness, a study of survey responses from doctors suggests. High-efficacy DMTs often are perceived to have…
Nearly 80% of adults with highly active relapsing-remitting multiple sclerosis (RRMS) were free of relapses or confirmed disability worsening two years after receiving stem cell transplant, according to a real-world study in Denmark. Moreover, more than two-thirds (69%) of these RRMS patients achieved a clinical outcome called NEDA-3, or…
Among four antibody-based therapies for multiple sclerosis (MS), Ocrevus (ocrelizumab) works best to prevent disability progression and other measures of disease activity in people with PPMS, or primary progressive MS, a review study found. However, the medication is associated with an increased risk of infection, data suggested.
An educational intervention program was found to help improve treatment adherence among people with multiple sclerosis (MS) receiving injectable therapies in a clinical trial in Iran. The program was designed based on the theory of planned behavior — a psychological premise that assumes people act rationally according to their…
Older people with multiple sclerosis (MS) who have not experienced disease activity for several years still will benefit from disease-modifying therapies (DMTs) to control the neurodegenerative disorder, a new study found. Data from a first trial assessing whether discontinuation of DMTs among these patients is at least as…